Shanxi Zhendong PharmaceuticalLtd Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Lianmin Yang

Algemeen directeur

CN¥678.5k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	2.9yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.9yrs
Gemiddelde ambtstermijn bestuur	2.6yrs

Recente managementupdates

Recent updates

Improved Revenues Required Before Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Stock's 39% Jump Looks Justified

Oct 22

We Think Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) Can Afford To Drive Business Growth

Sep 30

Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Low P/S No Reason For Excitement

Aug 08

Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Mar 07

CEO

Lianmin Yang (61 yo)

2.9yrs

Tenure

CN¥678,500

Compensatie

Mr. Lianmin Yang is President of Shanxi Zhendong Pharmaceutical Co.,Ltd from December 02, 2021 and had been its Deputy General Manager since April 24, 2021 and serves as its Director. He has M.B.A. from Ch...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Lianmin Yang	President & Director	2.9yrs	CN¥678.50k	geen gegevens
Changlu Liu	Head of Accounting & CFO	6.1yrs	CN¥375.40k	geen gegevens
Zheyu Wang	VP & Secretary of the Board of Director	1.5yrs	CN¥521.50k	geen gegevens
Xufeng Wang	Executive GM & Director	no data	geen gegevens	geen gegevens

2.9yrs

Gemiddelde duur

40yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 300158 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Lianmin Yang	President & Director	no data	CN¥678.50k	geen gegevens
Xufeng Wang	Executive GM & Director	1.6yrs	geen gegevens	geen gegevens
Zhixiang Jin	Supervisor	12.9yrs	geen gegevens	0.077% CN¥ 3.7m
Ren Hu Li	Chairman of the Supervisory Board	15.9yrs	geen gegevens	0.084% CN¥ 4.0m
Zhimin Wang	Director	15.9yrs	CN¥83.30k	geen gegevens
Jing Li	Director	6.3yrs	CN¥694.70k	geen gegevens
Kun Li	Director	2.6yrs	CN¥688.30k	geen gegevens
Lina Jin	Independent Director	less than a year	geen gegevens	geen gegevens
Wanliang Lv	Independent Director	less than a year	geen gegevens	geen gegevens
Xuemei Qin	Independent Director	9.4yrs	geen gegevens	geen gegevens
Jiawen Ai	Non-Independent Director	less than a year	geen gegevens	geen gegevens
Zhenhong Lei	Supervisor	less than a year	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300158 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.6 jaar), wat duidt op een nieuw bestuur.

Shanxi Zhendong PharmaceuticalLtd Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Board and Non-Employee Supervisor Elections

High number of new directors

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

Less than half of directors are independent

Less than half of directors are independent

No independent directors

Recent updates

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: EPS: CN¥0.009 (vs CN¥0.018 loss in 3Q 2023)

Improved Revenues Required Before Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Stock's 39% Jump Looks Justified

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Q3, 2024 Results on Oct 24, 2024

We Think Shanxi Zhendong PharmaceuticalLtd (SZSE:300158) Can Afford To Drive Business Growth

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Board and Non-Employee Supervisor Elections

Second quarter 2024 earnings released: EPS: CN¥0.007 (vs CN¥0.014 in 2Q 2023)

Shanxi Zhendong Pharmaceutical Co.,Ltd's (SZSE:300158) Low P/S No Reason For Excitement

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 27, 2024

High number of new directors

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: CN¥0.043 loss per share (vs CN¥0.05 loss in FY 2022)

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 23, 2024

Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Now 20% undervalued

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Apr 23, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: CN¥0.018 loss per share (vs CN¥0 in 3Q 2022)

Now 21% undervalued after recent price drop

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: CN¥0.014 (vs CN¥0.015 in 2Q 2022)

Full year 2022 earnings released: CN¥0.05 loss per share (vs CN¥2.55 profit in FY 2021)

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0 (vs CN¥0.10 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.015 (vs CN¥0.12 in 2Q 2021)

Upcoming dividend of CN¥2.70 per share

Investor sentiment improved over the past week

Shanxi Zhendong Pharmaceutical Co.,Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 09 May 2022

No independent directors

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves 2021 Profit Distribution Plan

Investor sentiment deteriorated over the past week

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 22, 2022

Shanxi Zhendong Pharmaceutical Co.,Ltd Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.087 in 3Q 2020)

Investor sentiment deteriorated over the past week

FountainVest Capital Partners Fund IV, L.P., a fund managed by Fountain Vest Capital Partners GP4 Ltd. entered into an agreement to acquire Beijing Zhendong Langdi Pharmaceutical Co., Ltd. from Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) for CNY 5.8 billion.

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.055 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Final Profit for 2020

Shanxi Zhendong Pharmaceutical Co.,Ltd Announces Final Profit Distribution Proposal for 2020

Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.14 in FY 2019)

New 90-day low: CN¥4.39

Investor sentiment deteriorated over the past week

New 90-day low: CN¥5.46

New 90-day low: CN¥5.73

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Q3, 2020 Results on Oct 27, 2020

New 90-day high - CN¥6.39

New 90-day high - CN¥6.05

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report First Half, 2020 Results on Aug 21, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd